Pediatric indication granted to Nexium
Esomeprazole approved for children.
AstraZeneca has received Nexium) for use in children ages one to 11 years for the short-term treatment of gastrointestinal reflux disease (GERD). Both the delayed-release capsule and the liquid formulations have been approved for the new indication. Approved dosing of the proton pump inhibitor is 10 mg to 20 mg per day for children one to 11 years of age and a 20- to 40-mg daily dose for adolescents 12 to 17 years old.
To see more Daily News articles, click here.
To go to the Drug Topics homepage, click here.
Socioeconomic Disparities Persisted Alongside Improving Vaccination Rates In US Over 11-Year Period
April 16th 2024Findings indicating that socioeconomic disparities widened gaps in vaccination timeliness signal the need for increased efforts to promote timely vaccination among children from families with lower income and those without private insurance.
FDA Expands Tenofovir Alafenamide Indication to Treat HBV in Patients as Young as 6
March 28th 2024Tenofovir alafenamide was originally approved by the FDA in 2016 to treat adults with chronic HBV infection with compensated liver disease and in 2022 to treat pediatric patients aged 12 years and older.
